Camilla Simpson

Camilla Simpson has over two decades of business and strategy experience across a diverse group of organizations: from seed investments to public companies. Camilla has demonstrated a proven track record in delivering novel products for multiple disease indications to global markets in areas of high unmet medical need throughout her career. Currently, Camilla is the Managing Member and President of Rare Strategic, LLC, where she provides strategic advice to venture-backed companies. Prior to this, Camilla held numerous executive leadership positions, including SVP, Head of Product Portfolio Development at BioMarin Pharmaceutical Inc., Global Head of Regulatory Affairs at BioMarin Pharmaceutical Inc., and VP Global Regulatory Strategy- Early Development and Business Development at Shire Pharmaceuticals. Ms. Simpson serves as an independent member of the Board of Directors of Spruce Biosciences and is a member of the Scientific Advisory Board of Aristea Therapeutics. Ms. Simpson received a BSc from National University of Ireland, Galway, a BSc Hons, from Kingston University, UK, and an MSc with distinction from Birkbeck College, University of London.